Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Acrux Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Michael Kotsanis

İcra Kurulu Başkanı

AU$702.0k

Toplam tazminat

CEO maaş yüzdesi	68.4%
CEO görev süresi	9.9yrs
CEO sahipliği	0.5%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	9.9yrs

Son yönetim güncellemeleri

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

Nov 16

CEO Tazminat Analizi

Michael Kotsanis'un ücretlendirmesi Acrux'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$702k	AU$480k	-AU$6m
Mar 31 2024	n/a	n/a	-AU$3m
Dec 31 2023	n/a	n/a	-AU$709k
Sep 30 2023	n/a	n/a	-AU$736k
Jun 30 2023	AU$710k	AU$463k	-AU$764k
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$8m
Sep 30 2022	n/a	n/a	-AU$9m
Jun 30 2022	AU$670k	AU$446k	-AU$10m
Mar 31 2022	n/a	n/a	-AU$10m
Dec 31 2021	n/a	n/a	-AU$10m
Sep 30 2021	n/a	n/a	-AU$11m
Jun 30 2021	AU$645k	AU$468k	-AU$13m
Mar 31 2021	n/a	n/a	-AU$12m
Dec 31 2020	n/a	n/a	-AU$11m
Sep 30 2020	n/a	n/a	-AU$10m
Jun 30 2020	AU$510k	AU$452k	-AU$9m
Mar 31 2020	n/a	n/a	-AU$10m
Dec 31 2019	n/a	n/a	-AU$11m
Sep 30 2019	n/a	n/a	-AU$10m
Jun 30 2019	AU$521k	AU$451k	-AU$8m
Mar 31 2019	n/a	n/a	-AU$9m
Dec 31 2018	n/a	n/a	-AU$9m
Sep 30 2018	n/a	n/a	-AU$12m
Jun 30 2018	AU$690k	AU$406k	-AU$14m

Tazminat ve Piyasa: Michael 'nin toplam tazminatı ($USD 483.64K ), Australian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 313.13K ).

Tazminat ve Kazançlar: Michael 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Michael Kotsanis (58 yo)

9.9yrs

Görev süresi

AU$701,959

Tazminat

Mr. Michael John Kotsanis, BSc, GradDipBus, MBus has been Chief Executive Officer and Managing Director of Acrux Limited since November 03, 2014. He served as an Independent Non-Executive Director at IDT A...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Kotsanis	CEO, MD & Executive Director	9.9yrs	AU$701.96k	0.52% A$ 81.6k
Geoffrey Edward Brooke	Independent Non-Executive Director	8.3yrs	AU$84.65k	0.58% A$ 91.3k
Ross Dobinson	Independent Non-Executive Chairman	26.6yrs	AU$131.11k	1.81% A$ 283.5k
Timothy Oldham	Independent Non-Executive Director	11yrs	AU$84.65k	0.52% A$ 82.1k
Donald Brumley	Independent Non-Executive Director	3.3yrs	AU$84.01k	1.17% A$ 183.4k

9.9yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ACR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.9 yıldır).

Acrux Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Acrux Limited, Annual General Meeting, Nov 29, 2023

Independent Non-Executive Director recently bought AU$92k worth of stock

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Less than half of directors are independent

Recent updates

New major risk - Financial position

Full year 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2023)

Acrux Limited to Report First Half, 2024 Results on Feb 23, 2024

Acrux Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.035 loss in FY 2022)

New minor risk - Financial data availability

New minor risk - Share price stability

Independent Non-Executive Director recently bought AU$92k worth of stock

First half 2023 earnings released: AU$0.011 loss per share (vs AU$0.019 loss in 1H 2022)

Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: AU$0.035 loss per share (vs AU$0.057 loss in FY 2021)

Acrux's Sixth Generic Dossier Accepted by FDA for Review

Less than half of directors are independent

Non-Executive Director recently bought AU$89k worth of stock

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Acrux Limited Announces Fifth Generic Dossier Accepted by FDA for Review

Acrux Limited Launches Testosterone Topical Solution USP, 30mg Per Actuation

Full year 2021 earnings released: AU$0.057 loss per share (vs AU$0.056 loss in FY 2020)

CFO & Company Secretary Deborah Ambrosini has left the company

Acrux Receives Approval from the FDA for Its Generic Version of Jublia

Non Executive Director Norman Gray has left the company

Acrux Confirms Patent Challenge

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Acrux Limited Announces the US Food and Drug Administration Approves its Generic Product Based on Perrigo's Testosterone Topical Solution, 30mg/1.5mL

New 90-day high: AU$0.21

Acrux Limited announced that it expects to receive AUD 7.815143 million in funding from Bioscience Managers Pty Ltd and other investors

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Acrux Limited Signs Licensing Agreement with Dash Pharmaceuticals

Full year earnings released - AU$0.057 loss per share

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş